CUPERTINO, Calif. – Feb. 26, 2008 – Alliacense today announced that Advanced Medical Optics, Inc. (AMO) has purchased a Moore Microprocessor Patent™ (MMP) Portfolio license from The TPL Group.
AMO is engaged in the development, manufacture and marketing of medical devices for the eye, including diagnostic instruments as well as products used in ocular surgery and laser vision correction.
”AMO is dedicated to improving the quality of vision for others through a full range of advanced refractive technologies,” said Carl Silverman, Vice President, Licensing for Alliacense. “We are pleased that AMO has joined the rapidly growing list of MMP Portfolio licensees.”
The sweeping scope of applications using MMP Portfolio design techniques continues to encourage the world’s leading manufacturers of end user products from around the globe to become MMP Portfolio licensees. Over 40 global companies from the US, Europe, Japan, Korea and Taiwan have licensed the MMP Portfolio technologies.
The MMP Portfolio patents, filed by The TPL Group in the 1980s, cover techniques that enable higher performance and lower cost designs, and are fundamental to consumer and commercial digital systems ranging from DVD players, cell phones and portable music players to communications infrastructure, medical equipment and automobiles.
About the MMP Portfolio
The Moore Microprocessor Patent Portfolio contains intellectual property that is jointly owned by the privately-held TPL Group and publicly-held Patriot Scientific Corporation (OTCBB: PTSC). The MMP Portfolio includes seven U.S. patents as well as their European and Japanese counterparts. It is widely recognized that the MMP Portfolio protects fundamental technology used in microprocessors, microcontrollers, digital signal processors (DSPs), embedded processors and system-on-chip (SoC) devices. Manufacturers of microprocessor-based products can learn more about how to participate in the MMP Portfolio Licensing Program by contacting: mmp-licensing@alliacense.com.
About Advanced Medical Optics (AMO)
AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems. AMO also supplies a full line of contact lens care products, as well as products used in cataract/implant procedures. AMO is based in Santa Ana, California, and employs over 4,000 worldwide. The company has operations in more than 20 countries and markets products in approximately 60 countries. For more information, visit the company’s Website at www.amo-inc.com.
About Alliacense
Alliacense is a TPL Group Enterprise executing best-in-class design and implementation of Intellectual Property (IP) licensing programs. As a cadre of IP licensing strategists, technology experts, and experienced business development/management executives, Alliacense focuses on expanding the awareness and value of TPL’s IP portfolios. Founded in 1988, The TPL Group has emerged as a coalition of high technology enterprises involved in the development, management and commercialization of proprietary product technologies as well as the design, manufacture and sales of proprietary products based on those technologies and corresponding IP assets. For more information, visit www.alliacense.com.
# # #
Alliacense and Moore Microprocessor Patent (MMP) are trademarks of Technology Properties Limited (TPL). All other trademarks belong to their respective owners